News
News
Press Release
Sysmex Partners with QIAGEN for Exclusive Distribution and Supply of Clinical Diagnostic Products in Infectious Diseases and Oncology in Japan
Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) and QIAGEN K.K. (HQ: Chuo-ku, Tokyo, Japan; President and Representative Director: Xunlong Lin; “QIAGEN”), the Japanese subsidiary of QIAGEN N.V., announced today that they entered into a strategic alliance agreement for clinical diagnostic products in the field of molecular diagnosis1 on September 30, 2025.
This agreement marks the enhancement of collaboration between the two companies in the field of clinical diagnostics based on the global alliance agreement signed in 2024. Sysmex and QIAGEN will now partner for distribution for QIAGEN’s clinical diagnostic instruments, reagents, and other products in the field of infectious diseases and oncology for Japan, and will promote their introduction into the Japanese medical institution and testing center markets.
The two companies have now concluded an exclusive agreement for the distribution and supply of QIAGEN’s clinical diagnostic instruments, reagents, and other products for infectious diseases and oncology in the Japanese market. With this agreement, in addition to the sale of existing cancer genetic companion diagnostic products2, they will establish a sales collaboration in the field of infectious diseases, which accounts for roughly half of the total genetic testing market in this country.3
They will initially begin by handling existing products for clinical testing, including cancer molecular diagnostics and tuberculosis testing involving the market-leading QuantiFERON-TB Gold Plus test4 in the Japanese market, and will subsequently consider expanding the product lineup. By distributing the products of QIAGEN, a leader in the field of infectious diseases based on a broad platform of molecular diagnostic technologies, through Sysmex, which has a robust sales network for clinical testing products, the two companies aim to deliver products tailored to customer needs as quickly as possible to customers and to deliver more appropriate services more effectively.
Under the global strategic alliance agreement, Sysmex and QIAGEN will continue to strengthen their partnership by expanding their collaborative framework for product sales and exploring joint R&D initiatives that leverage the technological foundation of both companies. The two companies will contribute to improving patients’ quality of life and realizing optimal healthcare by developing and promoting high-value products globally.
| Release dated August 6, 2024: “Sysmex Expands Strategic Alliance Agreement with QIAGEN in the Field of Genetic Testing” | |
| https://www.sysmex.co.jp/en/news/2024/240806.html |
| 1 | Identifying diseases by studying the proteins, DNA, RNA, and other molecules contained in tissues and body fluids | |
| 2 | Gene testing kits for blood cancer, colorectal cancer, and non-small cell lung cancer, and reagents for monitoring therapeutic gains on chronic myelogenous leukemia, etc. |
|
| https://www.sysmex.co.jp/en/news/2015/150401.html | ||
| https://www.sysmex.co.jp/en/news/2020/200106.html | ||
| 3 | Source: The World Market for Molecular Diagnostics, 13th Edition (Published: December 19, 2024) | |
| 4 | QuantiFERON-TB Gold Plus test assesses the cell-mediated immune response to TB-specific antigens through a quantitative measurement of IFN-γ in a whole blood sample. |
About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. For more information about Sysmex, please visit www.sysmex.co.jp/en/.
* "Healthcare journey" is a trademark of Sysmex Corporation, registered in Japan.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.
- The purpose of this news release is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this news release is current as of the date of the announcement but may be subject to change without prior notice.